Effects of the platelet-activating factor antagonist BN 52021 on anti-islet cytotoxicity of mononuclear cells and serum from type 1 (insulin-dependent) diabetic patients.
The effect of platelet-activating factor (PAF) antagonist BN 52021 (0.06-2.5 mM) on the cytotoxic activity of mononuclear cells (MNC) from newly diagnosed type 1 diabetic patients against 51Cr-labeled Langerhans islets from neonatal rats was investigated in a 6-hour cytotoxicity test. A dose-dependent inhibition of anti-islet cytotoxicity by BN 52021 was observed. The suppression of the islet lysis was significant at a concentration of 0.6 mM BN 52021. During a 4-day cell culture, BN 52021 had no inhibitory effect on the antigen-mediated triggering of immunocytes with anti-islet cytotoxicity. The results suggest that the drug is only effective during immunocytolytic reactions of MNC against pancreatic islets. A PAF-independent action of BN 52021 can not be excluded at present.
Köhler
E
E
Institute of Diabetes Gerhardt Katsch, Karlsburg, FRG.
Varnai
G
G
Knospe
S
S
Förster
W
W
Michaelis
D
D
Wanka
H
H
D000293:Adolescent; D000328:Adult; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D004224:Diterpenes; D004305:Dose-Response Relationship, Drug; D005260:Female; D046934:Ginkgolides; D006801:Humans; D066298:In Vitro Techniques; D007515:Islets of Langerhans / Q000276:immunology*; D007783:Lactones / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology*; D008297:Male; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones; D010972:Platelet Activating Factor; C045856:ginkgolide B